MACROGENICS INC
MacroGenics, Inc. (NASDAQ: MGRC) is a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for cancer treatment. The company generates its pipeline of product candidates from proprietary antibody technology platforms, including antibody-drug conjugates (ADCs) and… From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What MACROGENICS INC does
In the company’s own words
MacroGenics, Inc. (NASDAQ: MGRC) is a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for cancer treatment. The company generates its pipeline of product candidates from proprietary antibody technology platforms, including antibody-drug conjugates (ADCs) and multi-specific antibodies utilizing its DART and TRIDENT platforms. MacroGenics maintains a commercial-scale cGMP antibody manufacturing facility at its Maryland headquarters, which supports both internal clinical programs and provides outsourced contract development and manufacturing services to collaborators and third parties.
The company's wholly-owned clinical pipeline includes three primary product candidates: lorigerlimab, a bispecific DART molecule targeting PD-1 and CTLA-4 checkpoint inhibitors; MGC026, an ADC targeting B7-H3; and MGC028, a first-in-class ADC targeting ADAM9. MacroGenics also maintains economic rights to three FDA-approved products: TZIELD (teplizumab-mzwv) for type 1 diabetes, ZYNYZ (retifanlimab-dlwr) for Merkel cell carcinoma and squamous cell carcinoma of the anal canal, and MARGENZA (margetuximab-cmkb) for HER2-positive breast cancer, which was sold to TerSera Therapeutics in November 2024.
Strategic collaborations represent a significant component of MacroGenics' business model. The company has generated over $1.6 billion in non-dilutive funding since inception through partnerships with global biopharmaceutical companies. A notable collaboration with Gilead Sciences involves MGD024, a next-generation CD123 × CD3 DART molecule for hematologic malignancies, with potential milestone payments reaching approximately $1.6 billion across three programs.
The company's intellectual property portfolio includes 58 U.S. patents with 24 pending applications and 681 patents in other countries with 283 pending applications, providing protection across its Fc Optimization, DART, and TRIDENT platforms. Manufacturing partnerships include agreements with Incyte, Emergent BioSolutions, and TerSera for contract development and manufacturing services. MacroGenics competes in the oncology therapeutics market against numerous major pharmaceutical and biotechnology companies with substantially greater resources.
Company details
- Sector
- Healthcare
- Industry
- Pharmaceutical Preparations
- Headquarters
- Rockville, MD
- Fiscal year end
- December
- CIK
- 1125345
- SIC
- 2834
Financial performance, year by year
Fiscal 2013–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns MACROGENICS INC — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · MACROGENICS INC’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do MACROGENICS INC and its peers compare on margins and cash generation over ten years?”
- “Where did five years of MACROGENICS INC's earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in MACROGENICS INC's last four quarterly filings that the numbers alone won't show?”